Flow of study participants

John J.P. Kastelein, et al. Circulation 2006;114:1729-1735

Dosing and follow-up schedule

John J.P. Kastelein, et al. Circulation 2006;114:1729-1735

Subject Demographics and Baseline Lipid Characteristics*

John J.P. Kastelein, et al. Circulation 2006;114:1729-1735

Adverse Events Considered Related to Study Medication by Dosage

John J.P. Kastelein, et al. Circulation 2006;114:1729-1735

Dose-dependent effect of ISIS 301012 on apoB levels

John J.P. Kastelein, et al. Circulation 2006;114:1729-1735

John J.P. Kastelein, et al. Circulation 2006;114:1729-1735

Dose-dependent effect of ISIS 301012 on LDL cholesterol levels

ApoB and LDL-C Levels by Mean Percent Change Relative to Baseline*

John J.P. Kastelein, et al. Circulation 2006;114:1729-1735